Reimagining Medicine Q2 2023 Results
Company overview
Financial review
Conclusions
Appendix
References
STRATEGY
Novartis Board endorses 100% spin-off of Sandoz, which will now go
to shareholder vote at EGM in September
Key milestones achieved
CMDs held in
New York and
London
Roadshows
with major
shareholders
Diverse and
experienced
Sandoz Board
and leadership
appointed1
Novartis Board
endorses
100% spin-off
Next steps
August 2023: EGM invitation, Shareholder
Brochure and listing prospectus²
September 15: Extraordinary General
Meeting (EGM), for shareholder vote
Early Q4 2023: Spin-off expected upon
shareholders approval³
3. In addition to shareholder approval, completion of the proposed Sandoz spin-off remains subject to certain conditions
CMD Capital Markets Day. 1. One Board member still to be announced. 2. Minimum 20 days before EGM.
precedent, such as no material adverse events, receipt of necessary authorizations as well as tax rulings and opinions.
26 Investor Relations | Q2 2023 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation